Phathom Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 332.72, 538.65, 748.88, 904.79, 1020.18 ], "ebit_estimate": [ 4.43, 159.13, 313.43, 435.95, 517.4 ], "ebitda_estimate": [ 10.16, 141.16, 275.29, 477.33, 581.22 ], "net_income_estimate": [ -43.33, 112.18, 267.85, 392.29, 473.64 ], "per_share_eps_estimate": [ -0.57, 1.24, 2.89, 3.76, 4.4 ], "eps_nri_estimate": [ -0.64, 1.16, 2.82, 3.94, 4.63 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -38.7, 112.01, 269.16, 385.87, 496.9 ], "operating_cash_flow_per_share_estimate": [ -0.64, -1.13, -6.22, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 80.52, 80.56, 80.48, 80.33, 80 ], "operating_cash_flow_estimate": [ -52.51, -92.72, -510.36, null, null ], "pettm_estimate": [ 0, 10.14, 4.36, 3.36, 2.87 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "62.28", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 62.28, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -2.34, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 73.93, 92.97, 108.31, 103.21, 119.97, 138.17, 157.53, 152.7 ], "ebit_estimate": [ -5.61, 7.8, 18.58, 13.3, 24.55, 41.8, 58.5, 47.8 ], "ebitda_estimate": [ -1.96, 13.72, 19.38, 17.5, 15.1, 22.7, 30.4, null ], "net_income_estimate": [ -18.19, -4.51, 6.61, 1.85, 15.25, 32.45, 49.15, 32.8 ], "per_share_eps_estimate": [ -0.23, -0.07, 0.07, 0.02, 0.19, 0.4, 0.59, 0.4 ], "eps_nri_estimate": [ -0.24, -0.08, 0.05, 0.04, 0.19, 0.4, 0.59, 0.4 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -16.88, -3.47, 8.07, 1.85, 15.25, 32.45, 49.15, 32.8 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 80, 80, 80, 80, 80, 80, 80, 80 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 61.81, 18.82, 10.6, 8.03, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "62.28", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 62.28, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -2.34, "future_operating_cash_flow_per_share_estimate_growth": null }